|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 23, 2016 ) The Parkinson Disease Medical Industry Report shows that it is caused by the progressive loss of dopamine-producing neurons in the substantia nigra within the basal ganglia. The main motor symptoms are tremors, bradykinesia and rigidity, although symptoms vary between individuals. As the disease progresses to more advanced stages, increasing symptoms and complications develop, which can cause severe disability in patients.
The current market offers a number of anti-PD treatment options which provide symptomatic relief. Levodopa is currently the gold standard therapy, with other drug classes including dopamine agonists and Monoamine Oxidase B (MAO-B) inhibitors also used to treat early and advanced cases. With no current treatment showing effectiveness in delaying the course of the disease, PD remains incurable. The high unmet need for a disease-modifying therapy is reflected in the pipeline, where a high proportion of early-stage first-in-class programs target the potential pathogenic mechanisms underlying neurodegeneration.
Other Key Points in Report:
PD is a crowded market with many neuromodulatory drug classes available. However, a disease-modifying therapy with neuroprotective effects is yet to be developed.
-What are the primary mechanisms that are thought to contribute to neuronal death?
-What are the major barriers facing the development of investigational neuroprotective candidates?
Analysis reveals a high level of innovation and diversity in the pipeline, with 121 first-in-class programs acting on 57 unique molecular targets.
Neuromodulatory targets remain the dominant target family, particularly in the late-stage pipeline.
-What are the first-in-class families with a significant presence?
-How well do they align with the underlying pathways governing neuronal death in PD?
Some of the first-in-class targets have a potentially stronger chance of being translated into novel treatments for PD.
-What is the scientific rationale behind these targets? How do they perform in Preclinical studies?
-What are the commonly used disease models and the parameters measuring neuroprotective effects in PD animal studies?
Inquire before Buying Report@ http://www.reportsweb.com/inquiry&RW0001170042/buying
Table of Content: An Overview
2 Executive Summary 4
2.1 High Unmet Needs Remain in Parkinson's Disease Market 4
2.2 Diverse and Innovative Pipeline to Shift Focus to Disease Modification 4
2.3 Deals Landscape Presents Substantial Investment Opportunities 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Epidemiology 9
4.3 Disease Etiology 10
4.3.1 Exposure to Environmental Toxins 10
4.3.2 Genetic Causes of Familial Parkinson's Disease 10
4.3.3 Susceptibility Genes for Parkinson's Disease 12
4.4 Disease Pathophysiology 12
4.4.1 Basal Ganglia Anatomy and Physiology 12
4.4.2 Process Underlying Neurodegeneration 15
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001170042/discount
4.5 Disease Symptoms 19
4.6 Co-morbidities and Complications 19
4.7 Diagnosis 19
4.8 Classification of Disease Stages 20
4.8.1 Hoehn and Yahr Scale 20
4.8.2 Unified Parkinson's Disease Rating Scale 20
4.8.3 Scale for the Assessment of Positive Symptoms 22
4.8.4 Mini Mental State Examination 22
4.9 Prognosis and Disease Staging 22
4.10 Treatment Options 23
4.10.1 Pharmacotherapy 23
4.10.2 Non-pharmacological Treatment 25
4.11 Overview of Marketed Products 25
4.11.1 Molecule Type and Target Analysis 26
4.11.2 Treatment Algorithm 27
4.12 Current Unmet Needs 33
5 Assessment of Pipeline Product Innovation 35
5.1 Parkinson's Disease Pipeline by Molecule Type, Phase and Therapeutic Target 35
5.2 Comparative Distribution of Programs between Parkinson's Disease Market and Pipeline by Therapeutic Target Family 40
5.3 First-in-Class Pipeline Programs Targeting Novel Molecular Targets 40
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001170042/buy/6995
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
